Heather E Olson1,2, Julia G Costantini2, Lindsay C Swanson2, Walter E Kaufmann3, Timothy A Benke4, Anne B Fulton5, Ronald Hansen5, Annapurna Poduri1, Gena Heidary2,5. 1. Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA. 2. Department of Neurology, CDKL5 Center of Excellence, Boston Children's Hospital, Boston, MA, USA. 3. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA. 4. Neurology, Pharmacology and Otolaryngology, School of Medicine Departments of Pediatrics, Children's Hospital Colorado, University of Colorado, Aurora, CO, USA. 5. Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Abstract
AIM: To characterize the neuro-ophthalmological phenotype of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) and assess visual acuity as a reproducible, quantitative outcome measure. METHOD: We retrospectively analyzed clinical data from patients with CDD. Complete neuro-ophthalmological assessments, including visual acuity, were evaluated. RESULTS: Of 26 patients (22 females, four males; median age 4y, interquartile range 2y 1mo-7y 10mo), cerebral visual impairment (CVI), defined as visual dysfunction in the absence of ocular or anterior visual pathway abnormalities, was diagnosed in all those over 2 years of age. Ophthalmological examinations revealed nystagmus in 10 patients and strabismus in 24 patients. Visual acuity was measured in 24 patients, by preferential looking in all and by sweep visual evoked potential in 13. Visual acuities were lower than age expectations and demonstrated improvement in the first 3 years. Adjusting for age and sex, average preferential looking visual acuity after 2 years of age was higher in patients with intact mobility than in those who were non-mobile. INTERPRETATION: CVI was observed in patients with CDD. Visual acuity improved over time and correlated with mobility. Visual acuity, as a quantifiable measure of visual function, should be considered as an outcome measure in pre-clinical and clinical studies for CDD. What this paper adds Cerebral visual impairment is highly prevalent in cyclin-dependent kinase-like 5 deficiency disorder (CDD). Visual acuity is a measurable quantitative outcome measure in CDD. Visual acuity in CDD correlates with gross motor ability.
AIM: To characterize the neuro-ophthalmological phenotype of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) and assess visual acuity as a reproducible, quantitative outcome measure. METHOD: We retrospectively analyzed clinical data from patients with CDD. Complete neuro-ophthalmological assessments, including visual acuity, were evaluated. RESULTS: Of 26 patients (22 females, four males; median age 4y, interquartile range 2y 1mo-7y 10mo), cerebral visual impairment (CVI), defined as visual dysfunction in the absence of ocular or anterior visual pathway abnormalities, was diagnosed in all those over 2 years of age. Ophthalmological examinations revealed nystagmus in 10 patients and strabismus in 24 patients. Visual acuity was measured in 24 patients, by preferential looking in all and by sweep visual evoked potential in 13. Visual acuities were lower than age expectations and demonstrated improvement in the first 3 years. Adjusting for age and sex, average preferential looking visual acuity after 2 years of age was higher in patients with intact mobility than in those who were non-mobile. INTERPRETATION: CVI was observed in patients with CDD. Visual acuity improved over time and correlated with mobility. Visual acuity, as a quantifiable measure of visual function, should be considered as an outcome measure in pre-clinical and clinical studies for CDD. What this paper adds Cerebral visual impairment is highly prevalent in cyclin-dependent kinase-like 5 deficiency disorder (CDD). Visual acuity is a measurable quantitative outcome measure in CDD. Visual acuity in CDD correlates with gross motor ability.
Authors: D Ricci; D Chieffo; D Battaglia; C Brogna; I Contaldo; V De Clemente; E Losito; Ch Dravet; E Mercuri; F Guzzetta Journal: Epilepsy Res Date: 2014-10-28 Impact factor: 3.045
Authors: Scott T Demarest; Heather E Olson; Angela Moss; Elia Pestana-Knight; Xiaoming Zhang; Sumit Parikh; Lindsay C Swanson; Katherine D Riley; Grace A Bazin; Katie Angione; Lisa-Marie Niestroj; Dennis Lal; Elizabeth Juarez-Colunga; Tim A Benke Journal: Epilepsia Date: 2019-07-16 Impact factor: 5.864
Authors: Teresa Randò; Adina Bancale; Giovanni Baranello; Margherita Bini; Anton Giulio De Belvis; Roberta Epifanio; Maria Flavia Frisone; Andrea Guzzetta; Giuseppe La Torre; Daniela Ricci; Sabrina Signorini; Francesca Tinelli; Enrico Biagioni; Pierangelo Veggiotti; Eugenio Mercuri; Elisa Fazzi; Giovanni Cioni; Francesco Guzzetta Journal: Epilepsia Date: 2004-07 Impact factor: 5.864
Authors: Stephanie Fehr; Helen Leonard; Gladys Ho; Simon Williams; Nick de Klerk; David Forbes; John Christodoulou; Jenny Downs Journal: J Neurodev Disord Date: 2015-01-05 Impact factor: 4.025
Authors: Jacinta Saldaris; Helen Leonard; Peter Jacoby; Eric D Marsh; Tim A Benke; Scott Demarest; Jenny Downs Journal: J Child Neurol Date: 2022-04-14 Impact factor: 2.363
Authors: Jenny Downs; Peter Jacoby; Jacinta Saldaris; Helen Leonard; Tim Benke; Eric Marsh; Scott Demarest Journal: J Sleep Res Date: 2022-04-12 Impact factor: 5.296
Authors: Sruti Raja; Batool Sahar Emadi; Eric D Gaier; Ryan A Gise; Anne B Fulton; Gena Heidary Journal: Front Hum Neurosci Date: 2021-10-27 Impact factor: 3.169
Authors: Joni N Saby; Patrick J Mulcahey; Alexis E Zavez; Sarika U Peters; Shannon M Standridge; Lindsay C Swanson; David N Lieberman; Heather E Olson; Alexandra P Key; Alan K Percy; Jeffrey L Neul; Charles A Nelson; Timothy P L Roberts; Timothy A Benke; Eric D Marsh Journal: Brain Commun Date: 2022-08-04